Constipation Incidence with Tirzepatide
Constipation occurs in approximately 2.5% of patients receiving tirzepatide, representing a 3-fold increased risk compared to placebo. This gastrointestinal side effect is dose-dependent and typically emerges during dose escalation, though it remains substantially less common than nausea (20%) or diarrhea (16%) 1.
Evidence-Based Incidence Rates
The most rigorous systematic review and meta-analysis of tirzepatide trials demonstrates:
- Tirzepatide group: 2.54% constipation rate
- Comparator group: 0.856% constipation rate
- Relative Risk: 3.08 (95% CI: 1.83-5.20; p < 0.0001) 1
This data derives from 6 randomized controlled trials encompassing 4,586 patients with type 2 diabetes receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg weekly 1.
Clinical Context and Comparative Risk
Constipation ranks as the least common major gastrointestinal adverse effect of tirzepatide, occurring far less frequently than:
- Nausea: 20.43% (RR 2.90)
- Diarrhea: 16.24% (RR 2.07)
- Decreased appetite: 9.64% (RR 5.04)
- Vomiting: 9.05% (RR 2.69)
- Dyspepsia: 7.13% (RR 2.52) 1
In non-diabetic populations with obesity, constipation rates remain consistent at approximately 12.5% in real-world observational studies 2, though a larger meta-analysis of patients without diabetes showed a relative risk of 2.85 (95% CI: 2.38-3.42) 3.
Dose-Dependent Relationship
The 2.5% incidence represents pooled data across all doses; higher doses (10-15 mg) carry greater constipation risk. Recent comparative data shows that maintaining tirzepatide at 2.5 mg versus escalating to 5 mg results in fewer gastrointestinal adverse events overall (35% vs 50%), though specific constipation rates at each dose were not separately reported 4.
Timing and Severity Patterns
Constipation typically:
- Manifests during dose escalation phases 5
- Peaks 2-3 days post-injection in symptomatic patients 6
- Presents as mild-to-moderate severity in most cases 2
- Rarely necessitates treatment discontinuation as an isolated symptom
Management Implications
When constipation develops, it can be severe enough to require intervention beyond standard laxatives. A case report documented successful management of tirzepatide-induced severe constipation using elobixibat (an ileal bile acid transporter inhibitor) after conventional laxatives failed, allowing continuation of therapy 6. This represents a mechanism-based approach targeting the specific motility deficits induced by incretin therapy.
The 2025 AACE guidelines emphasize that gastrointestinal side effects occur "most commonly during dose escalation" and recommend:
- Starting at the lowest dose (2.5 mg)
- Slow dose up-titration
- Monitoring which foods exacerbate symptoms
- Avoiding eating past fullness
- Smaller, more frequent meals 5
Important Caveats
The 2.5% figure represents controlled trial data and may underestimate real-world incidence, as clinical trials typically exclude patients with pre-existing severe gastrointestinal conditions. Additionally, patients who discontinue therapy early due to intolerable side effects may not be fully captured in intention-to-treat analyses.
The relative rarity of constipation compared to other GI effects (nausea, diarrhea) makes it a less common reason for treatment discontinuation, though when severe, it can significantly impact quality of life and adherence 6.